This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results-
Combination Radiation Therapy and Oncolytic Vaccinia Virus Therapy in Preclinical Models of Glioma
DownloadSpring 2017
Gliomas are the most common primary malignant brain tumour in adults, with glioblastoma multiforme (GBM), the most common and most deadly form of glioma, making up over half of all diagnosed cancers in the brain/central nervous system. The standard of care for gliomas has remained unchanged for...
-
Investigating Radiation in Combination with Oncolytic Vaccinia Virus to Improve the Treatment of Glioblastoma
DownloadFall 2023
Glioblastoma (GBM) is a malignant and immune-suppressed brain cancer that remains incurable despite the current standard of care. Radiotherapy is a mainstay of GBM treatment, however invasive cancer cells outside the irradiated field and radioresistance preclude complete eradication of GBM cells....
-
Novel Insights into the Role of O6-Methylguanine-DNA Methyltransferase in Glioblastoma Angiogenesis, Invasion, and Proliferation
DownloadFall 2012
Glioblastoma multiforme (GBM) is characterized by aberrant angiogenesis, rapid proliferation, and widespread invasion through the brain parenchyma. Thus, the prognosis for these tumors remains extremely poor despite aggressive multimodal treatment including chemotherapy with the alkylating agent...
-
Fall 2019
Glioblastoma (GBM), classified as WHO grade IV astrocytoma, is the most common and lethal adult primary brain tumour. Despite recent advances in treatment, GBM prognosis remains largely unchanged with most patients succumbing to the disease within ~15 months of diagnosis. This dismal outcome can...
-
Fall 2022
Background: Glioblastoma is the most common and aggressive malignant primary brain tumor. Despite aggressive standard treatment including surgery, radiation and chemotherapy, the median overall survival for patients with glioblastoma is only about 14 to 16 months. Using a glioblastoma TCGA...